The U.S. Food and Drug Administration (FDA) has revised its strain recommendation for the 2024-25 COVID-19 vaccines, now advising manufacturers to target the KP.2...
Neuraptive Therapeutics Receives Orphan Drug Designation from the FDA for NTX-001 in Peripheral Nerve Injury Treatment
Wayne, PA – Neuraptive Therapeutics Inc., a pioneering biotechnology...
